195 related articles for article (PubMed ID: 37291191)
1. Broad anti-pathogen potential of DEAD box RNA helicase eIF4A-targeting rocaglates.
Obermann W; Azri MFD; Konopka L; Schmidt N; Magari F; Sherman J; Silva LMR; Hermosilla C; Ludewig AH; Houhou H; Haeberlein S; Luo MY; Häcker I; Schetelig MF; Grevelding CG; Schroeder FC; Lau GSK; Taubert A; Rodriguez A; Heine A; Yeo TC; Grünweller A; Taroncher-Oldenburg G
Sci Rep; 2023 Jun; 13(1):9297. PubMed ID: 37291191
[TBL] [Abstract][Full Text] [Related]
2. Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors.
Chu J; Zhang W; Cencic R; Devine WG; Beglov D; Henkel T; Brown LE; Vajda S; Porco JA; Pelletier J
Cell Chem Biol; 2019 Nov; 26(11):1586-1593.e3. PubMed ID: 31519508
[TBL] [Abstract][Full Text] [Related]
3. Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor.
Iwasaki S; Floor SN; Ingolia NT
Nature; 2016 Jun; 534(7608):558-61. PubMed ID: 27309803
[TBL] [Abstract][Full Text] [Related]
4. The DEAD-box helicase eIF4A: paradigm or the odd one out?
Andreou AZ; Klostermeier D
RNA Biol; 2013 Jan; 10(1):19-32. PubMed ID: 22995829
[TBL] [Abstract][Full Text] [Related]
5. Exploring the targeting spectrum of rocaglates among eIF4A homologs.
Naineni SK; Cencic R; Robert F; Brown LE; Haque M; Scott-Talib J; Sénéchal P; Schmeing TM; Porco JA; Pelletier J
RNA; 2023 Jun; 29(6):826-835. PubMed ID: 36882295
[TBL] [Abstract][Full Text] [Related]
6. Coupling between the DEAD-box RNA helicases Ded1p and eIF4A.
Gao Z; Putnam AA; Bowers HA; Guenther UP; Ye X; Kindsfather A; Hilliker AK; Jankowsky E
Elife; 2016 Aug; 5():. PubMed ID: 27494274
[TBL] [Abstract][Full Text] [Related]
7. A parasitic fungus employs mutated eIF4A to survive on rocaglate-synthesizing
Chen M; Kumakura N; Saito H; Muller R; Nishimoto M; Mito M; Gan P; Ingolia NT; Shirasu K; Ito T; Shichino Y; Iwasaki S
Elife; 2023 Feb; 12():. PubMed ID: 36852480
[TBL] [Abstract][Full Text] [Related]
8. Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol.
Müller C; Obermann W; Schulte FW; Lange-Grünweller K; Oestereich L; Elgner F; Glitscher M; Hildt E; Singh K; Wendel HG; Hartmann RK; Ziebuhr J; Grünweller A
Antiviral Res; 2020 Mar; 175():104706. PubMed ID: 31931103
[TBL] [Abstract][Full Text] [Related]
9. Targeting the DEAD-Box RNA Helicase eIF4A with Rocaglates-A Pan-Antiviral Strategy for Minimizing the Impact of Future RNA Virus Pandemics.
Taroncher-Oldenburg G; Müller C; Obermann W; Ziebuhr J; Hartmann RK; Grünweller A
Microorganisms; 2021 Mar; 9(3):. PubMed ID: 33807988
[TBL] [Abstract][Full Text] [Related]
10. A forward genetic screen identifies modifiers of rocaglate responsiveness.
Shen L; Pugsley L; Cencic R; Wang H; Robert F; Naineni SK; Sahni A; Morin G; Zhang W; Nijnik A; Porco JA; Langlais D; Huang S; Pelletier J
Sci Rep; 2021 Sep; 11(1):18516. PubMed ID: 34531456
[TBL] [Abstract][Full Text] [Related]
11. Selective targeting of the DEAD-box RNA helicase eukaryotic initiation factor (eIF) 4A by natural products.
Shen L; Pelletier J
Nat Prod Rep; 2020 May; 37(5):609-616. PubMed ID: 31782447
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.
Steinhardt JJ; Peroutka RJ; Mazan-Mamczarz K; Chen Q; Houng S; Robles C; Barth RN; DuBose J; Bruns B; Tesoriero R; Stein D; Fang R; Hanna N; Pasley J; Rodriguez C; Kligman MD; Bradley M; Rabin J; Shackelford S; Dai B; Landon AL; Scalea T; Livak F; Gartenhaus RB
Blood; 2014 Dec; 124(25):3758-67. PubMed ID: 25320244
[TBL] [Abstract][Full Text] [Related]
13. Rocaglates as Antivirals: Comparing the Effects on Viral Resistance, Anti-Coronaviral Activity, RNA-Clamping on eIF4A and Immune Cell Toxicity.
Obermann W; Friedrich A; Madhugiri R; Klemm P; Mengel JP; Hain T; Pleschka S; Wendel HG; Hartmann RK; Schiffmann S; Ziebuhr J; Müller C; Grünweller A
Viruses; 2022 Mar; 14(3):. PubMed ID: 35336926
[TBL] [Abstract][Full Text] [Related]
14. RNA aptamers to initiation factor 4A helicase hinder cap-dependent translation by blocking ATP hydrolysis.
Oguro A; Ohtsu T; Svitkin YV; Sonenberg N; Nakamura Y
RNA; 2003 Apr; 9(4):394-407. PubMed ID: 12649492
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A.
Chen M; Asanuma M; Takahashi M; Shichino Y; Mito M; Fujiwara K; Saito H; Floor SN; Ingolia NT; Sodeoka M; Dodo K; Ito T; Iwasaki S
Cell Chem Biol; 2021 Apr; 28(4):475-486.e8. PubMed ID: 33296667
[TBL] [Abstract][Full Text] [Related]
16. Duplex unwinding and ATPase activities of the DEAD-box helicase eIF4A are coupled by eIF4G and eIF4B.
Özeş AR; Feoktistova K; Avanzino BC; Fraser CS
J Mol Biol; 2011 Sep; 412(4):674-87. PubMed ID: 21840318
[TBL] [Abstract][Full Text] [Related]
17. Comparative characterization of two DEAD-box RNA helicases in superfamily II: human translation-initiation factor 4A and hepatitis C virus non-structural protein 3 (NS3) helicase.
Du MX; Johnson RB; Sun XL; Staschke KA; Colacino J; Wang QM
Biochem J; 2002 Apr; 363(Pt 1):147-55. PubMed ID: 11903057
[TBL] [Abstract][Full Text] [Related]
18. eIF4A inhibitors PatA and RocA stack the deck against translation.
Ingolia NT
Structure; 2021 Jul; 29(7):638-639. PubMed ID: 34214439
[TBL] [Abstract][Full Text] [Related]
19. A helicase-independent activity of eIF4A in promoting mRNA recruitment to the human ribosome.
Sokabe M; Fraser CS
Proc Natl Acad Sci U S A; 2017 Jun; 114(24):6304-6309. PubMed ID: 28559306
[TBL] [Abstract][Full Text] [Related]
20. Novel eIF4A1 inhibitors with anti-tumor activity in lymphoma.
Kayastha F; Herrington NB; Kapadia B; Roychowdhury A; Nanaji N; Kellogg GE; Gartenhaus RB
Mol Med; 2022 Sep; 28(1):101. PubMed ID: 36058921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
